TG Therapeutics Secures $500M Non-Dilutive Boost, Expands Buyback Program
Event summary
- TG Therapeutics secured a $500M non-dilutive capital injection via a $750M senior secured credit facility with Blue Owl Capital.
- The facility replaces a $250M existing credit line and includes a $250M incremental capital option.
- TG Therapeutics expanded its share repurchase program from $100M to $300M, having already repurchased $38M of stock at an average price of $28.98 per share.
- The financing is earmarked for share repurchases, business development, and growth of BRIUMVI, its lead multiple sclerosis treatment.
The big picture
TG Therapeutics' $500M non-dilutive capital raise underscores its strategic pivot toward financial flexibility, enabling aggressive share buybacks and pipeline investments. The deal with Blue Owl Capital reflects a broader trend of biotech firms leveraging non-dilutive financing to bolster commercialization efforts without diluting equity. The expanded share repurchase program signals confidence in TG Therapeutics' ability to generate sustained cash flow from BRIUMVI, its flagship multiple sclerosis treatment.
What we're watching
- Debt Strategy
- How TG Therapeutics will balance the new $750M credit facility with its cash flow positive business model to avoid overleveraging.
- Shareholder Returns
- Whether the expanded $300M share repurchase program will enhance shareholder value amid market volatility.
- Pipeline Growth
- The pace at which TG Therapeutics advances its pipeline alongside commercializing BRIUMVI, given the new capital infusion.
Related topics